Nouvelle déclaration d'incident
No de la demande: 2015-3925
Numéro de référence du titulaire d'homologation: 2015TH265
Nom du titulaire (nom légal complet, aucune abbréviation): Bayer Inc
Adresse: 2920 Matheson Blvd
Ville: Mississauga
État: ON
Pays: Canada
Code postal /Zip: L9W 5R6
Incident chez un animal domestique
Pays: UNITED STATES
État: UNKNOWN
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation. 11556-155
Nom du produit: Seresto Collar - cat
Autre (préciser)
CollarOui
Autres unités: collar
Site: Animal / Usage sur un animal domestique
Autre
Cat / Chat
Domestic short hair
1
Femme
17
11
lbs
Cutanée
>1 mo <= 6 mos / > 1 mois < = 6 mois
>24 hrs <=3 days / >24 h <=3 jours
Système
Persisted until death
Oui
Oui
1
Day(s) / Jour(s)
Mort
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On 24-Jul-2013, a 17 year old, 11.00 pound, spayed female, Domestic Shorthair feline, in good condition, with a concomitant medical condition of hyperthyroidism, had 1 Seresto Cat collar (Flumethrin-Imidacloprid) placed around the neck by the owner. On 26 Jul 2013 the cat developed application site alopecia. On 27 Jul 2013 the cat became anorexic. The collar was removed and upon removal purulent discharge was noted at the application site. On 30 Jul 2013 the cat was seen by the veterinarian for continued anorexia. A CBC/Chem screen was performed; the results are pending. The cat was administered subcutaneous fluids and 1ml of maropitant citrate then discharged. On 06-Aug-2013, the patient was taken back to the veterinary clinic. While hospitalized, the at died. No necropsy was performed. No further information is expected. Case is closed
Mort
N- Unlikely. Death is not expected after product application as inconsistent with pharmaco-toxicological product profile. Information on reason of death limited (no necropsy report available). Time to onset not suggestive for product involvement either. Considering old age of cat and pre-existing hyperthyriodism, other etiologies are more probable, including renal problems. Transient mild application site disorders may occur in particularly sensitive animals shortly after product application. Onset time consistent. However, application site reactions such as purulent discharge are not expected with product use however may be a secondary effect. Reported anorexia is unspecific and might be linked to other underlying disease (e.g. infection). Considering all aspects, a product connection was considered unlikely.